However, we do want to be sure we're maintaining the quality, effectiveness, and safety of pulmonary rehab. I'm working with a group at the American Thoracic Society (ATS) to take this further ...

On May 18, at the 2025 American Thoracic Society (ATS) International Conference ... in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) and an eosinophilic ...

A symposium at the 2023 American Thoracic Society (ATS) International Conference featured research on predictors of chronic obstructive pulmonary disease (COPD) occurrence and disease progression.

On 18 May 2025, at the American Thoracic Society International Conference ... to reduce exacerbation rates in chronic obstructive pulmonary disease (COPD) patients with elevated blood eosinophil ...

1 The results are being presented at the American Thoracic Society (ATS) International Conference ... 65% of bio-eligible patients with COPD have a BEC greater than or equal to 150 cells/μL.

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

A range of posters presented at the 2023 American Thoracic Society (ATS) International Conference highlighted a plethora of risk factors for pulmonary conditions in adulthood outside of tobacco ...

At the 2024 ATS International Conference, Dr Christenson noted significant advancements in COPD research, highlighting promising clinical trial results for biologics targeting type 2 inflammation ...

The article is published in the Annals of the American Thoracic Society. COPD comprises several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants ...

Win ratio analysis of BOREAS and NOTUS: Faster trials, clearer wins for patients with chronic obstructive pulmonary disease with type 2 inflammation. Presented at: American Thoracic Society ...

Over the last 10 years, the ATS has published more than 43 clinical practice guidelines on various conditions, including COPD. Typically, only a minority of expert panel recommendations are strong ...

Verona Pharma plc has announced the upcoming presentation of ten posters at the American Thoracic Society Conference 2025, highlighting analyses from its Phase 3 ENHANCE studies of Ohtuvayre ...